Gold prices edged higher; remain near $3,400/oz as Sept rate cut bets rise
Neogen Corp 's (NASDAQ:NEOG) Chief Accounting Officer, John Patrick Moylan, recently acquired 10,000 shares of the company's common stock. The purchase, made on April 10, 2025, was executed at a price of $5.07 per share, amounting to a total transaction value of $50,700. The timing is notable as InvestingPro data shows the stock trading at $4.97, down nearly 40% in the past week, with technical indicators suggesting oversold conditions. This acquisition increases Moylan's direct ownership to 10,000 shares. The move comes as part of Moylan's ongoing involvement with Neogen Corp, a company specializing in in vitro and in vivo diagnostic substances. With a market capitalization of $1.07 billion and a current ratio of 3.91, InvestingPro analysis reveals the company maintains strong liquidity despite recent market challenges. Subscribers can access 10+ additional ProTips and comprehensive insider trading analysis in the Pro Research Report.
In other recent news, Neogen Corporation reported its fiscal Q3 2025 earnings, revealing an unexpected rise in earnings per share (EPS) to $0.10, surpassing the forecast of -$0.01. However, the company missed revenue forecasts, posting $221 million against the expected $232.36 million. Despite the EPS beat, Neogen revised its revenue and EBITDA guidance downward, indicating ongoing financial challenges. Guggenheim analysts adjusted their outlook on Neogen, reducing the price target to $13.00 from $15.00 but maintained a Buy rating, reflecting confidence in the company's long-term potential despite current headwinds. Neogen's Petrifilm product line is set to commence initial production in the upcoming fall season, representing a positive development. The company continues to face a challenging macroeconomic environment, with tariff uncertainties affecting operations. Neogen's focus remains on restructuring its genomics business and cost management to navigate these challenges.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.